53344357.e5
The long-term safety of BPC-157 for human use is not established, as no controlled clinical trials have examined sustained administration beyond short-term animal study durations
In a 2012 study published in the International Journal of Physiology, Pathophysiology and Pharmacology , KPV was found to suppress NF-B, which is known to induce the expression of inflammatory genes and regulate the survival, activation, and differentiation of inflammatory T cells.8 9 Having this suppressive property, KPV could be a potential treatment for serious inflammatory health conditions affecting the lungs or gastrointestinal tract, in which the NF-B pathway plays a key role.8 10 Indeed, a 2017 study in a mouse model observed that KPV administration led to significant downregulation of TNF-, a major cytokine encoded by the pro-inflammatory TNFA gene and which uses the NF-B pathway.11 12 As an antimicrobial In 2000, the Journal of Leukocyte Biology published an in vitro study describing the effect that KPV (and -MSH more broadly) could have on common pathogens
Metabolic reprogramming of synovial fibroblasts in osteoarthritis by inhibition of pathologically overexpressed pyruvate dehydrogenase kinases
Klockgether, T., Dller, G., Wllner, U., Petersen, D
